Evidence map›Paper›PMID 38961451›Full record

ArticleDiabetology & metabolic syndrome2024

Experimental investigation for nonalcoholic fatty pancreas management using probiotics.

Marwa Matboli, Hiba S Al-Amodi, Shaimaa Hamady, Marwa Ali, Marian Ms Roushdy, Amany Helmy Hasanin, Yasmin M Aboul-Ela, Reda Albadawy, Eman Gomaa, Hala F M Kamel and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology & metabolic syndrome, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Marwa MatboliMedical biochemistry and molecular biology department, Faculty of medicine, Ain Shams University, Cairo, 11566, Egypt. DrMarwa_Matboly@med.asu.edu.eg.
Hiba S Al-AmodiBiochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah, 21955, Saudi Arabia.
Shaimaa HamadyDepartment of Biochemistry, Faculty of Science, Ain Shams University, Cairo, 11566, Egypt. shaimaahamady@sci.asu.edu.eg.
Marwa AliMedical biochemistry and molecular biology department, Faculty of medicine, Ain Shams University, Cairo, 11566, Egypt.
Marian Ms RoushdyMedical biochemistry and molecular biology department, Faculty of medicine, Ain Shams University, Cairo, 11566, Egypt.
Amany Helmy HasaninClinical pharmacology department, Faculty of medicine, Ain Shams University, Cairo, Egypt.
Yasmin M Aboul-ElaClinical pharmacology department, Faculty of medicine, Ain Shams University, Cairo, Egypt.
Reda AlbadawyDepartment of Gastroenterology, Hepatology & Infectious Disease, Faculty of Medicine, Benha University, Benha, 13518, Egypt.
Eman GomaaHistology and Cell biology department, Faculty of Medicine, Ain Shams University, Giza, Egypt.
Hala F M KamelMedical biochemistry and molecular biology department, Faculty of medicine, Ain Shams University, Cairo, 11566, Egypt.
Hind A ELsawiDepartment of Internal Medicine, Badr University in Cairo, Badr City, Egypt.
Laila M FaridPathology department Faculty of Medicine, Ain Shams University, Giza, Egypt.
Mariam B AbouelkhairPathology department Faculty of Medicine, Ain Shams University, Giza, Egypt.
Gena M ElmakromyEndocrinology & Diabetes mellitus unit, Department of Internal Medicine, Badr University in Cairo, Badr City, Egypt.
Nesma Mohamed FawzyMedical biochemistry and molecular biology department, Faculty of medicine, Ain Shams University, Cairo, 11566, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNonalcoholic fatty pancreatitis (NAFP) presents a pressing challenge within the domain of metabolic disorders, necessitating further exploration to unveil its molecular intricacies and discover effective treatments. Our focus was to delve into the potential therapeutic impact of ZBiotic, a specially engineered strain of probiotic B. subtilis, in managing NAFP by targeting specific genes linked with necroptosis and the TNF signaling pathway, including TNF, ZBP1, HSPA1B, and MAPK3, along with their upstream epigenetic regulator, miR-5192, identified through bioinformatics.

methodsRats were subjected to either a standard or high-fat, high-sucrose diet (HFHS) for eight weeks. Subsequently, they were divided into groups: NAFP model, and two additional groups receiving daily doses of ZBiotic (0.5 ml and 1 ml/kg), and the original B. subtilis strain group (1 ml/kg) for four weeks, alongside the HFHS diet.

resultsZBiotic exhibited remarkable efficacy in modulating gene expression, leading to the downregulation of miR-5192 and its target mRNAs (p < 0.001). Treatment resulted in the reversal of fibrosis, inflammation, and insulin resistance, evidenced by reductions in body weight, serum amylase, and lipase levels (p < 0.001), and decreased percentages of Caspase and Nuclear Factor Kappa-positive cells in pancreatic sections (p < 0.01). Notably, high-dose ZBiotic displayed superior efficacy compared to the original B. subtilis strain, highlighting its potential in mitigating NAFP progression by regulating pivotal pancreatic genes.

conclusionZBiotic holds promise in curbing NAFP advancement, curbing fibrosis and inflammation while alleviating metabolic and pathological irregularities observed in the NAFP animal model. This impact was intricately linked to the modulation of necroptosis/TNF-mediated pathway-related signatures.

Indexed as

B. subtilis, obesityNecroptosis, TNF pathwayNonalcoholic fatty pancreasZBiotic

Identifiers

PMID38961451
PMCPMC11223304

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.